What is KLRS stock price today?

KLRS (Kalaris Therapeutics Inc) stock is trading at $5.87 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is KLRS stock going up or down today?

KLRS stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy KLRS stock now?

The decision to buy KLRS depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is KLRS a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for KLRS based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is KLRS stock overvalued or undervalued?

Use our DCF valuation calculator to determine if KLRS is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is KLRS's P/E ratio?

P/E ratio data for KLRS will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is KLRS's market cap?

KLRS (Kalaris Therapeutics Inc) has a market capitalization of $0.14 billion, making it a small-cap stock.

What is KLRS's price to book ratio?

KLRS trades at a price-to-book (P/B) ratio of 1.83, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does KLRS pay dividends?

KLRS does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is KLRS's dividend yield?

KLRS does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is KLRS stock a good long-term investment?

KLRS's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is KLRS's revenue growth rate?

Revenue growth data for KLRS is available on our dashboard with detailed financial statement analysis.

Profitability metrics for KLRS are available on our dashboard with complete income statement analysis.

What are the risks of investing in KLRS?

Key risks for KLRS include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does KLRS compare to its competitors?

Compare KLRS to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize KLRS's performance and positioning.

What is KLRS's stock price target for 2026?

Our AI model provides price targets for KLRS based on fundamental analysis: Bull case $7.63 (+30%), Base case $6.75 (+15%), Bear case $5.28 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about KLRS?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for KLRS. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is KLRS's next earnings report?

KLRS reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

KLRS - Kalaris Therapeutics Inc

NYSE * Health Care * Biotechnology

$5.87

+$0.05 (+0.86%)

About Kalaris Therapeutics Inc

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.

KLRS Key Statistics

Market Cap

$144.68M

P/B Ratio

1.83

EPS

$-2.85

Employees

How KLRS Compares to Peers

KLRS is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

N/A

of 5

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
KLRS(This stock)	$144.68M	N/A	0%	0.0%	-
AMGNAmgen Inc	$189.19B	24.7	0%	0.2%	vs AMGN
GILDGilead Sciences	$174.33B	20.7	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$113.01B	29.0	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$79.87B	18.2	0%	0.3%	vs REGN
BIIBBiogen Inc	$26.50B	20.5	-0%	0.1%	vs BIIB

Kalaris Therapeutics Inc Company Information

Headquarters: Massachusetts; U.S.A
Website: kalaristx.com
Sector: Health Care
Industry: Biotechnology

Data Updated: April 16, 2026 at 7:20 PM EDT

Ready to invest in KLRS?

Commission-free trading available. Affiliate links.

KLRS Lician Score

5% confidence

4.0/10

Neutral

KLRS has a Lician Score of 4/10 (Average). Areas of concern: Growth.

value

5.0

growth

2.0

quality

5.0

momentum

5.0

safety

5.0

The Lician Score is a comprehensive 1-10 rating that evaluates KLRSacross five key dimensions: Value (valuation relative to sector),Growth (revenue and earnings trajectory),Quality (profitability and balance sheet strength),Momentum (price trends and analyst sentiment), andSafety (volatility and risk metrics).

KLRS Financial Snowflake

5-axis analysis across key investment dimensions

4.4/10

Neutral

5.0

Value

Valuation vs. sector peers

2.0

Growth

Revenue & earnings trajectory

5.0

Quality

Profitability & moat strength

5.0

Momentum

Price trends & analyst sentiment

5.0

Safety

Financial stability & risk

Upcoming Events for KLRS

Dashboard

Enter a ticker to analyze